Intuitive Surgical's 2025 earnings were strong, and the future remains bright, with valuation as the only big concern for investors.
Intuitive Surgical (NasdaqGS:ISRG) received FDA clearance for its da Vinci 5 system to be used in certain cardiac procedures.
If you are wondering whether Intuitive Surgical at around US$525 a share still makes sense for your portfolio, the key ...
With nine new procedures cleared for the da Vinci 5 robot, Intuitive’s strategy includes working with a limited number of U.S ...
Intuitive Surgical receives FDA clearance for the da Vinci 5 robot to be used in cardiac procedures, reports 18% procedure ...
Intuitive Surgical, Inc. ISRG is expected to grow earnings by the double digits in 2026 and 2027. This Zacks Rank #1 (Strong Buy) is still the industry leader in robotic-assisted surgery. Intuitive ...
The FDA 510(k) clearances for cardiac procedures cover Intuitive's latest-generation da Vinci 5 (DV5) using non-Force ...
The robotics giant revealed on an earnings call that it won FDA clearance for several cardiac procedures and is also ramping up its presence in ambulatory surgery centers.
Investing.com -- TD Cowen initiated coverage of Intuitive Surgical with a Buy rating and a $660 price target, saying the launch of the da Vinci 5 system is driving a long-tailed product cycle that can ...
The company's revenue is accelerating with strong profit margins. Shares of Intuitive Surgical stock look expensive right now. Here's why shares of Intuitive Surgical rose this week, and whether you ...
Intuitive Surgical is a leader in the field of surgical robotics. The company has 10,763 surgical robots in place worldwide. Its robots are seeing strong demand -- and that should continue. Innovation ...
Intuitive Surgical (NASDAQ: ISRG) reports in-line Q4 results, sets measured guidance for 2026, with an 18% revenue growth and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results